Q0243 — Injection, casirivimab and imdevimab, 2400 mg
Q0243 is a HCPCS Level II code for injection, casirivimab and imdevimab, 2400 mg. It belongs to the Temporary Codes section. It was terminated on December 12, 2024 and is not valid on new claims.
This code has been terminated
CMS terminated Q0243 on December 12, 2024. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for Q0243
- Long descriptor
- Injection, casirivimab and imdevimab, 2400 mg
- Short descriptor
- Casirivimab and imdevimab
- Added
- November 21, 2020
- Terminated
- December 12, 2024
- BETOS
- O1G
- Pricing indicator
- 54 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Vaccinations.
Codes adjacent to Q0243
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If Q0243 is not quite right, the correct code is very often within a few positions of it.
- Q0222Injection, bebtelovimab, 175 mgterminated
- Q0224Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg
- Q0234Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg
- Q0235Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg
- Q0237Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0238Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0239Injection, bamlanivimab-xxxx, 700 mgterminated
- Q0240Injection, casirivimab and imdevimab, 600 mgterminated
- Q0244Injection, casirivimab and imdevimab, 1200 mgterminated
- Q0245Injection, bamlanivimab and etesevimab, 2100 mgterminated
- Q0247Injection, sotrovimab, 500 mgterminated
- Q0249Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0477Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only
- Q0478Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type
- Q0479Power module for use with electric or electric/pneumatic ventricular assist device, replacement only
- Q0480Driver for use with pneumatic ventricular assist device, replacement only
Questions about Q0243
What is HCPCS code Q0243?
Q0243 is a HCPCS Level II code for injection, casirivimab and imdevimab, 2400 mg. It sits in the Temporary Codes section.
Does Medicare cover Q0243?
The CMS HCPCS file marks Q0243 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is Q0243 still valid?
No. Q0243 was terminated on December 12, 2024 and should not be used on new claims.